TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
CSL ( (AU:CSL) ) just unveiled an announcement.
CSL Limited has announced an update regarding its ongoing on-market buy-back program, with a total of 49,785 ordinary fully paid securities bought back on the previous day, adding to a cumulative total of 2,185,583 securities. This buy-back initiative is part of CSL’s strategy to optimize its capital structure and potentially enhance shareholder value, reflecting the company’s robust financial health and commitment to efficient capital management.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$225.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, focusing on the development and manufacturing of innovative biopharmaceutical products. The company is known for its work in plasma therapies, vaccines, and other specialty medicines, serving a global market with a strong emphasis on research and development.
Average Trading Volume: 1,250,126
Technical Sentiment Signal: Sell
Current Market Cap: A$86.95B
See more insights into CSL stock on TipRanks’ Stock Analysis page.